FDA Drug Recalls

Recalls / Class II

Class IID-66447-002

Product

Irinotecan Hydrochloride Injection, 100 mg/5 mL (20 mg/mL), 1 x 5 mL Single Dose Vial per carton, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Schiffgraben 23, 38690 Vienenburg, Germany; Distributed by: West-Ward Pharmaceutical Corp., Eatontown, NJ 07724 USA, NDC 0143-9701-01.

Brand name
Irinotecan Hydrochloride
Generic name
Irinotecan Hydrochloride
Active ingredient
Irinotecan Hydrochloride
Route
Intravenous
NDCs
0143-9701, 0143-9702
FDA application
ANDA091032
Affected lot / code info
Lot #: AC0026, AC0027, Exp 10/14

Why it was recalled

Superpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to determine the amount of irinotecan to use in formulation which will result in an assay higher than the labeled claim.

Recalling firm

Firm
West-Ward Pharmaceutical Corp.
Manufacturer
Hikma Pharmaceuticals USA Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
465 Industrial Way W, N/A, Eatontown, New Jersey 07724-2209

Distribution

Quantity
9813 vials
Distribution pattern
Nationwide

Timeline

Recall initiated
2013-09-23
FDA classified
2013-11-04
Posted by FDA
2013-11-13
Terminated
2016-04-05
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-66447-002. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.